These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17696796)

  • 1. Darunavir (TMC114): a new HIV-1 protease inhibitor.
    Molina JM; Hill A
    Expert Opin Pharmacother; 2007 Aug; 8(12):1951-64. PubMed ID: 17696796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance.
    Taiwo BO; Hicks CB
    AIDS Read; 2007 Mar; 17(3):151-6, 159-61. PubMed ID: 17396332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
    Arazo Garcés P; Omiste Sanvicente T
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():23-31. PubMed ID: 19195456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.
    Robertson J; Feinberg J
    Expert Opin Pharmacother; 2012 Jun; 13(9):1363-75. PubMed ID: 22594781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
    Pozniak A; Opravil M; Beatty G; Hill A; de Béthune MP; Lefebvre E
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1275-80. PubMed ID: 18844462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darunavir: pharmacokinetics and drug interactions.
    Back D; Sekar V; Hoetelmans RM
    Antivir Ther; 2008; 13(1):1-13. PubMed ID: 18389894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darunavir: a second-generation protease inhibitor.
    Busse KH; Penzak SR
    Am J Health Syst Pharm; 2007 Aug; 64(15):1593-602. PubMed ID: 17646561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
    Boffito M; Miralles D; Hill A
    HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
    Hill A; Moyle G
    HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darunavir: a nonpeptidic antiretroviral protease inhibitor.
    McCoy C
    Clin Ther; 2007 Aug; 29(8):1559-76. PubMed ID: 17919539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darunavir.
    El-Atrouni WI; Temesgen Z
    Drugs Today (Barc); 2007 Oct; 43(10):671-9. PubMed ID: 17987220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.
    Arastéh K; Clumeck N; Pozniak A; Lazzarin A; De Meyer S; Muller H; Peeters M; Rinehart A; Lefebvre E;
    AIDS; 2005 Jun; 19(9):943-7. PubMed ID: 15905675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
    Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
    Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
    Rachlis A; Clotet B; Baxter J; Murphy R; Lefebvre E
    HIV Clin Trials; 2007; 8(4):213-20. PubMed ID: 17720661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.
    McKeage K; Scott LJ
    Paediatr Drugs; 2010 Apr; 12(2):123-31. PubMed ID: 20218748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
    Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
    Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
    Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
    AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
    Kakuda TN; Brochot A; Tomaka FL; Vangeneugden T; Van De Casteele T; Hoetelmans RM
    J Antimicrob Chemother; 2014 Oct; 69(10):2591-605. PubMed ID: 24951533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.